Neonatal encephalopathy and hypoxic-ischemic encephalopathy

Handb Clin Neurol. 2019:162:217-237. doi: 10.1016/B978-0-444-64029-1.00010-2.

Abstract

Acute hypoxic-ischemic encephalopathy around the time of birth remains a major cause of death and life-long disability. The key insight that led to the modern revival of studies of neuroprotection was that, after profound asphyxia, many brain cells show initial recovery from the insult during a short "latent" phase, typically lasting approximately 6h, only to die hours to days later after a "secondary" deterioration characterized by seizures, cytotoxic edema, and progressive failure of cerebral oxidative metabolism. Studies designed around this framework showed that mild hypothermia initiated as early as possible before the onset of secondary deterioration and continued for a sufficient duration to allow the secondary deterioration to resolve is associated with potent, long-lasting neuroprotection. There is now compelling evidence from randomized controlled trials that mild to moderate induced hypothermia significantly improves survival and neurodevelopmental outcomes in infancy and mid-childhood.

Keywords: Animal models; Apoptosis; Hypoperfusion; Hypotension; Hypoxic–ischemic encephalopathy; Necrosis; Therapeutic hypothermia; Window of opportunity for treatment.

Publication types

  • Review

MeSH terms

  • Adult
  • Animals
  • Brain Diseases / congenital*
  • Brain Diseases / therapy*
  • Female
  • Humans
  • Hypothermia, Induced
  • Hypoxia-Ischemia, Brain / congenital*
  • Hypoxia-Ischemia, Brain / therapy*
  • Infant, Newborn
  • Infant, Newborn, Diseases / therapy*
  • Pregnancy